<DOC>
	<DOC>NCT00764829</DOC>
	<brief_summary>We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.</brief_summary>
	<brief_title>Blood Samples to Evaluate Biomarkers of Donor Chimerism</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Diagnosed with a hematologic disease or malignancy Scheduled to receive nonablative conditioning with fludarabine and total body irradiation Donor is wellmatched by high resolution DNA techniques. Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral calcineurin inhibitor. Age &gt;18 years at the time of enrollment. Exclusion criteria: Diagnosed with an immunodeficiency disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>fludarabine</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>biomarkers</keyword>
</DOC>